挤出-滚圆法制备凝胶骨架型双氯芬酸钾缓释微丸

目的采用挤出滚圆法制备出稳定性良好的双氯芬酸钾缓释微丸。方法通过挤出滚圆法制备双氯芬酸钾缓释微丸。以制剂体外释放度及加速试验中制剂稳定性为指标,筛选了骨架剂的种类和卡波姆974P用量等影响因素。结果以卡波姆974P为凝胶型骨架剂,载药量为25%(w)时,制备微丸的释放度符合日本药典标准(0.5 h释放20⁴5%(w),2 h释放4045%(w),2 h释放40⁷0%(w),8 h释放70%(w)以上)。结论成功地制备了双氯芬酸钾凝胶骨架型缓释微丸,该制备工艺重现性好,具有理想的缓释效果,加速试验稳定性良好。     

挤出滚圆法制备盐酸索他洛尔骨架缓释微丸

目的制备盐酸索他洛尔骨架缓释微丸,研制盐酸索他洛尔新剂型。方法采用挤出滚圆法制备盐酸索他洛尔骨架缓释微丸,考察润湿剂用量、挤出速度及滚圆速度对释放度的影响。结果 120 mL 3%PVP K30水溶液作为润湿剂(物料固定为400 g),以挤出速度35 r.min-1,滚圆速度500 r.min-1(1 min)进行盐酸索他洛尔缓释微丸的制备,制剂稳定性良好。结论本方法制备盐酸索他洛尔骨架缓释微丸工艺可靠,质量可控。     

挤出滚圆法制备吲哚美辛缓释微丸

目的:制备吲哚美辛(IMC)缓释微丸并考察其体外释放行为。方法:采用挤出滚圆法制备微丸,以微丸收率为考察指标,优选挤出速率、滚圆速度和滚圆时间参数水平;以体外释药曲线为考察指标,崩解剂微晶纤维素(MCC)、骨架材料羟丙甲基纤维素(HPMC)和润湿剂水的处方用量为因素,设计单因素试验筛选辅料处方,并进行处方验证试验及其释药机制研究。结果:优选的较佳工艺参数为挤出速度65r.min-1、滚圆速度650r.min-1、滚圆时间3min;优选的处方为MCC19、HPMC20、水6mL;验证试验表明所制得的IMC缓释微丸释放度重现性好且符合缓释制剂的要求,其释药机制为药物扩散和骨架溶蚀的混合型机制。结论:挤出滚圆法制备IMC缓释微丸方法可行,且制剂具有良好的体外缓释效果。     

尼群地平缓释微丸的制备及体外释放影响因素考察

目的:对影响尼群地平缓释微丸中药物体外释放的制备工艺因素进行考察。方法:采用挤出滚圆法制备尼群地平缓释微丸,通过体外释放度试验,对影响缓释微丸中药物释放的润湿剂乙醇浓度及用量、挤出速度、滚圆转速及滚圆时间等因素进行考察,优化制备工艺条件。结果:润湿剂用量及乙醇浓度对药物体外释放影响显著,乙醇浓度应在35%以下,用量宜控制在44mL左右。挤出速度、滚圆转速及滚圆时间等对药物体外释放有一定的影响,分别以48r.min-1、1400r.min-1、5min为宜。结论:采用上述制备工艺,可制得释药速度符合要求的尼群地平缓释微丸。     

挤出滚圆法制备氢溴酸右美沙芬骨架缓释微丸

目的以乙基纤维素和硬脂酸为骨架材料 ,采用挤出滚圆法制备氢溴酸右美沙芬骨架缓释微丸。方法以圆整度和释放度为评价指标 ,先对工艺因素 (挤出速度 ,滚圆速度 ,滚圆时间及热处理温度 )和处方因素 (乙基纤维素与硬脂酸的比例 ,微晶纤维素的用量 ,润湿剂的用量 )进行了单因素考察 ,然后进一步采用正交设计对其优化。结果优化条件所得缓释微丸外观圆整 ,粒子大小分布均匀 ,具有明显的缓释特性。结论通过以上处方和工艺可以制备具有 1 2h缓释的骨架微丸     

盐酸普萘洛尔骨架型缓释微丸的制备及处方工艺优化

目的制备盐酸普萘洛尔骨架型缓释微丸,并对其体外释药情况进行研究。方法采用挤出-滚圆法制备盐酸普萘洛尔骨架型缓释微丸,研究工艺及处方因素对盐酸普萘洛尔骨架型缓释微丸的制备和释放度的影响,采用星点-效应面优化法确定最优处方。结果确定最优处方的质量分数及工艺参数为:乙基纤维素(EC)9.06%、十八醇(octadecanol)48.03%、微晶纤维素(MCC)22.91%、无水乙醇适量,挤出速度30 r.min-1、滚圆转速1 377 r.min-1、滚圆时间40 min。结论盐酸普萘洛尔骨架型缓释微丸体外释药缓慢、持续、平稳。     

去甲斑蝥素骨架型缓释微丸的工艺优化

目的:优化去甲斑蝥素骨架型缓释微丸的制备工艺,并考察制剂体外释药特性.方法:采用挤出-滚圆技术制备去甲斑蝥素骨架型缓释微丸,以多因素综合评价指标,正交设计与多元回归分析相结合优化处方工艺.结果:以微晶纤维素(MCC)9.877%、乙基纤维素(EC)-硬脂酸(1:1.5)、黏合剂1%羟丙甲纤维素(HPMC)13 mL,80℃烘干制得的去甲斑蝥素骨架型缓释微丸具有较好的缓释效果.结论:采用挤出-滚圆技术,通过缓释材料制备的去甲宽蝥素骨架型缓释微丸,其体外释药缓慢、持续、平稳.     

熔融法制备非诺贝特缓释胶囊的处方工艺研究

目的 采用熔融法固体分散体技术代替微丸技术制备非诺贝特缓释胶囊。 方法 将主药与辅料熔融制备缓释颗粒,装入胶囊,以进口品为对照,按国家颁布的质量标准中释放度检查条件考查其释放。 结果 两者体外释放基本一致。 结论 熔融法固体分散体技术制备非诺贝特缓释胶囊较微丸技术简单方便,适合工业生产。     

银杏叶提取物-蒺藜总皂苷缓释微丸的制备研究

目的制备银杏叶提取物-蒺藜总皂苷（GBE-GSTT）缓释微丸。方法采用挤出制粒滚圆法制备素丸,以微球圆整度、堆密度、脆碎度和收率为指标,通过正交试验选出优化处方工艺,用乙基纤维素进行缓释包衣。结果缓释包衣微丸在1h释放量约为20％,无明显突释现象;4h释放量约为55％,8h可达80％以上,基本符合中国药典对缓释制剂的要求。微丸体外释放符合一级动力学模型。结论本工艺制备GBE—GSTT缓释微丸可行,操作简便,质量稳定。     

中心复合设计法优化丹七有效部位缓释微丸

目的:应用挤出滚圆法制备丹七提取物缓释微丸,研究微丸制备的最佳工艺和处方.方法:用挤出滚圆机制备丹七提取物缓释微丸;采用单因素考察和中心复合设计筛选最优处方和工艺条件;考察了微丸粉体学性质、收率和体外溶出度.结果:用挤出滚圆法制备的微丸圆整度好,大小均匀,收率高,药物体外溶出具有明显的缓释作用,体外释放曲线符合Peppas和Higuchi方程.结论:该工艺简便易行.     

复方盐酸二甲双胍缓释胶囊的制备及体外释放度考察

目的:研制复方盐酸二甲双胍缓释胶囊,并对盐酸二甲双胍(MH)和格列美脲进行释放度研究。方法:采用挤出滚圆法制备MH微丸,以乙基纤维素水分散体进行包衣,得到MH缓释微丸;采用混合物研磨法,结合湿法制粒技术得到格列美脲速释颗粒。将MH缓释微丸与格列美脲颗粒混合灌装成胶囊。结果:释放度测定结果表明,制得胶囊满足格列美脲在45 min内迅速释放,MH可在12 h内持续缓慢释放。结论:优选工艺稳定,复方盐酸二甲双胍缓释胶囊具有较好的速释、缓释效果。     

卡托普利缓释微丸的制备

目的:研制卡托普利缓释微丸.方法:采用挤出-滚圆法制备载药丸芯,以乙基纤维素水分散体(surelease)作为包衣材料,考察包衣增重对释放度的影响.结果:所制得的缓释微丸在2、5和10 h的释放率分别为标示量的15%～35%,40%～65%和75%以上,释药行为符合零级动力学.结论:制备工艺简单易行,适合工业化生产.     

Controlled drug release from Gelucire-based matrix pellets: experiment and theory

The aim of this work was to elucidate the underlying drug release mechanisms from lipidic matrix pellets, using theophylline and Gelucire 50/02 as model drug and carrier material, respectively. Pellets were prepared by two different techniques: melt-solidification and extrusion-spheronization. The effects of different formulations and processing parameters on the resulting drug release kinetics in 0.1N HCl and phosphate buffer pH 7.4 were studied and the obtained results analyzed using adequate mathematical models in order to get further insight into the underlying mass transport mechanisms. The type of preparation technique was found to strongly affect the underlying drug release mechanisms. Drug release from pellets prepared by the melt-solidification method was primarily controlled by pure diffusion, whereas drug release from pellets prepared by the extrusion-spheronization method was purely diffusion-controlled only at early time points. After approximately 2h, the pellets started to disintegrate, resulting in decreased diffusion pathway lengths and, thus, increased drug release rates. Furthermore, the curing conditions significantly affected the theophylline release kinetics, whereas varying the initial drug loading from 20 to 50% (w/w) resulted only in a slight increase in the relative drug release rate. Interestingly, the effects of the size of pellets prepared by the melt-solidification method on the resulting drug release kinetics could be quantitatively predicted using an analytical solution of Fick's second law of diffusion. These predictions could be verified by independent experiments.     

Powdered cellulose as excipient for extrusion-spheronization pellets of a cohesive hydrophobic drug.

This study compared a powdered cellulose (PC) and a microcrystalline cellulose (MCC) as sole excipients in the preparation of furosemide pellets by extrusion-spheronization. Pellets prepared with PC and 25 or 50% furosemide showed smaller mean size, a broader particle size distribution, similar sphericity, greater surface roughness and higher friability than equivalent pellets prepared with MCC. Furosemide release rate was markedly higher from PC pellets, which may be attributable to their higher micropore volume.     

Evaluating tamsulosin hydrochloride-released microparticles prepared using single-step matrix coating

The purpose of the present study was to prepare matrix extended release pellets of diclofenac potassium using low amount of release-modifying agents and, to compare its performance in vivo with coated pellets and matrix tablets. Coated pellets were prepared by extrusion-spheronization, followed by double layer coating using different polymers separately. Matrix pellets with different release rate in vitro were prepared by extrusion-spheronization with different kinds of retarding materials. Bioavailability study of different coated pellets revealed that the drug concentration in plasma of beagle dogs was too low to be detected and, implied that the drug was nearly not released from the preparations before reaching colon due to the appearance of lag time in the dissolution process. The phenomenon indicated that slow-release pellets of diclofenac potassium perhaps should not be developed as double membrane-controlled type. The AUC((0 → 24)) of the immediate release pellets, the two matrix pellets and the reference were 304.4, 87.7, 204.1 and 179.1 μg h/ml, respectively. The C(max) of the formulations mentioned above were 46.3, 13.0, 33.6 and 32.1 μg/ml, respectively. All the matrix formulations, including the reference, exhibited incomplete absorption due to the short small intestine transit time and termination of the drug release in the colon because of its limited solubility. The matrix pellets were bioequivalent with the commercially available tablet (Voltaren(?)) although the drug release in vitro of the former was much faster, while the bioavailability of the matrix pellets with similar in vitro drug release to the reference (Voltaren(?)) was much lower than the latter. The results perhaps was caused by lacking of physical robustness in the waxy tablet formulation, resulted in low wet strength and easily destroyed by the mechanical destructive forces and finally introduced faster drug release rate in vivo. It is apparent that preparations with similar performance in vitro may differ a lot in vivo because of the differences in drug release rate in vivo owing to various wet strengths of excipients contained, especially for sustained release products.     

尼莫地平速释微丸及缓释微丸的制备

目的研究尼莫地平速释微丸及缓释微丸的制备方法。方法通过溶剂蒸发-沉积法制备尼莫地平速释型及缓释型固体分散体;应用挤出-滚圆技术和离心造粒技术制备尼莫地平速释微丸及缓释微丸。结果依据处方1、2、3,采用挤出-滚圆技术制得的尼莫地平缓释微丸于1、3、5、12、18h的累积溶出百分率分别为18%、34%、49%、79%、100%;12%、18%、24%、36%、51%;42%、55%、61%、90%、100%。依据处方4、5得到速释微丸于45、90 min的累积溶出百分率分别为92%、100%;80%、89%,符合速释制剂的溶出要求。由处方6、7制备的缓释微丸于1、3、5、12、18h的累积溶出百分率分别为35%、48%、53%、77%、92%;30%、40%、47%、56%、80%。结论以国家食品药品监督管理局国家药品标准WS1-(X-171)-2003Z为依据设计的尼莫地平微丸处方较理想,制备工艺简单易行,值得广泛应用于尼莫地平微丸的工业生产。     

挤出滚圆法制备尼群地平缓释微丸的处方因素考察

目的 对影响药物释放的处方因素进行考察.方法 以微晶纤维素（MCC）为成型辅料，乙基纤维素（EC）为缓释材料，可溶性高分子材料为致孔剂，乳糖、十二烷基硫酸钠（SDS）及崩解剂为释药速度调节剂，采用挤出滚圆法制备尼群地平固体分散体及微丸，通过体外释放度试验对各辅料的种类及用量进行详细考察。结果 在尼群地平含量为10％的前提下，EC（10cps）用量在20％左右有一定的缓释作用；致孔剂采用PVPkm用量应在5％以下；崩解剂种类及用量对微丸中药物的释放影响显著，4％～12％的交联羧甲基纤维素钠（CCNa）可使药物释放较为完全；乳糖及SDS对药物释放无明显影响，用量分别为20％和4％较佳；成球辅料MCC型号为AvicelPH101。结论 采用上述处方，可制得体外释放度符合要求的尼群地平缓释微丸。     

挤出滚圆法制备阿莫西林微丸的处方工艺研究

目的 应用挤出滚圆法制备阿美西林微丸,研究微丸制备的最佳工艺和处方.方法 采用挤出滚圆造粒机制备阿莫西林微丸;采用单因素考察和正交设计筛选最优化处方及工艺条件;评价了微丸的粉体学性质、收率和体外溶出度.结果 用挤出滚圆法制备的阿莫西林微丸在30min内体外溶出均达80%以上,且圆整度好,收率高.结论 挤出滚圆法制备阿莫...